Skip to content
lifestyle.careersavvy.co.uk
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Sagimet Biosciences Inc.
Sagimet To Present Positive Full 52-Week Results from License Partner Ascletis’ Phase 3 Open-Label Extension Clinical Trial of Denifanstat in Acne and Mechanistic Data at the 2026 Fall Clinical Dermatology Conference
October 9, 2026
Sagimet Biosciences Announces Closing of Underwritten Offering of Series A Common Stock and Pre-Funded Warrants
October 1, 2026
Sagimet Biosciences Announces Pricing of $115.0 Million Underwritten Offering of Series A Common Stock and Pre-Funded Warrants
September 30, 2026
Sagimet Announces Positive Full 52-Week Results from License Partner Ascletis’ Phase 3 Open-Label Extension Clinical Trial of Denifanstat in Acne Presented at EADV 2026
September 30, 2026
Sagimet Biosciences to Host Virtual KOL Event, “Denifanstat Update: 52-Week Data from Phase 3 Open-Label Extension in China and Planned AURORA Phase 3 Clinical Trial in US” on September 30, 2026
September 28, 2026
Sagimet Biosciences Announces Participation in Two Upcoming Investor Conferences
September 2, 2026
Sagimet Biosciences Advances AURORA U.S. Phase 3 Trial of Denifanstat in Acne Toward Patient Enrollment in Q4 2026
August 25, 2026
Sagimet Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
August 17, 2026
Sagimet Biosciences Receives FDA “Study May Proceed” Letter and IND Clearance for Phase 3 Trial in Acne in Adolescent and Adult Patients
August 13, 2026
Sagimet Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
August 11, 2026
1
2
3
Next Page
→